Related Experiment Video
Updated: Jan 24, 2026

Combining Multiplex Fluorescence In Situ Hybridization with Fluorescent Immunohistochemistry on Fresh Frozen or Fixed Mouse Brain Sections
Published on: June 25, 2021
Ivabradine and metoprolol in fixed dose combination: When, why and how to use it
V Katsi1, G Skalis2, M S Kallistratos3
1Cardiology Department, Hippokration Hospital, Athens, Greece.
Insights
Heart rate is a key factor in heart disease. While beta-blockers are common, new research suggests ivabradine added to beta-blockers offers a better therapeutic option for coronary artery disease and heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart rate is a significant factor in coronary artery disease (CAD) and heart failure.
- While epidemiological studies suggest a pathogenetic role for heart rate, clinical trials have yielded limited strong evidence.
- Beta-blockers are the primary drugs for heart rate control, but their effectiveness is increasingly questioned.
Purpose of the Study:
- To evaluate the role of heart rate as a therapeutic target in cardiovascular diseases.
- To explore the need for additional therapies beyond beta-blockers for heart rate management.
- To investigate ivabradine as a novel therapeutic option in stable coronary disease and heart failure.
Main Methods:
- Review of epidemiological and clinical studies on heart rate in cardiovascular diseases.
- Analysis of recent studies assessing beta-blocker effectiveness in heart rate control and patient outcomes.
- Examination of clinical trial data for ivabradine as an add-on therapy to beta-blockers.
Main Results:
- Beta-blockers show insufficient effectiveness in heart rate control and their impact on outcomes is debated.
- There is a clear need for additional therapeutic strategies for heart rate management.
- Ivabradine, a selective heart rate inhibitor, demonstrates potential as an effective add-on therapy.
Conclusions:
- Heart rate remains an important risk marker and therapeutic target in CAD and heart failure.
- Ivabradine, when added to beta-blockers, represents a promising new therapeutic option for patients with stable coronary disease and heart failure.
Abstract:
Heart rate is an important factor in coronary artery disease and its manifestations, and as such has been considered as a possible target for therapy. Although in epidemiological, and in less degree, in clinical studies derived indications of a possible pathogenetic role of heart rate in major cardiac diseases, clinical trials did not provided any strong evidence. However, even as a simple risk marker, remains important in the treatment of coronary artery disease and heart failure. Beta-blockers are the drugs most frequently used for heart rate control. However, recent studies constantly find insufficient effectiveness of beta-blockers in heart rate control and go further to question their efficacy on outcomes, making clear the need for an additional therapy. Ivabradine, a pure heart rate inhibitor, added to classic beta-blocker treatment represent the new therapeutic option in stable coronary disease and heart failure.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dose Size and Dosing Frequency: Determination Methods
Fixed Action Patterns
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Fixing Double-strand Breaks

